Former Names B6.Cg-Tg(tTALap)5Bjd/J (Changed: 01-AUG-11 ) B6.Cg-Tg(tTALap)5Uh/J (Changed: 15-DEC-04 ) Type Congenic; Mutant Strain; Transgenic; Additional information on Genetically Engineered and Mutant Mice. Visit our online Nomenclature tutorial. Additional information on Congenic nomenclature. Species laboratory mouse Donating Investigator IMR Colony, The Jackson Laboratory
Hemizygous mice are viable and fertile. These transgenic mice carry the gene encoding the tetracycline-controlled transactivator protein (tTA) driven by the liver-enriched activator protein (PLAP, C/EBP, Cebpb) promoter, and express tTA, specifically, in liver. When these transgenic mice are mated to a strain carrying the luciferase gene coupled to a tetracycline-responsive promoter element (TRE; tetO), the luciferase reporter is expressed in a liver-specific fashion; treatment with doxycycline (dox) prevented transcription of the luciferase reporter in the liver. C57BL/6J-Tg(tTALap)5Uh mice may be mated to transgenic strains containing a gene of interest coupled to a TRE to study the effects of liver specific expression of the target gene in a dox-inducible fashion. Dox concentration may be administered in the animals' water supply. It should be noted that the chromosomal integration site of a TRE-couple transgene may affect the tissue-specific expression of the target gene, such that target gene expression is not limited to liver.
This strain originated on a mixed FVB/N,NMRI-outbred background and has been bred to a C57BL/6 background.
Strains carrying Tg(Cebpb-tTA)5Bjd alleleView Strains carrying Tg(Cebpb-tTA)5Bjd (2 strains)Strains carrying other alleles of tTA
008079 129S-Ppargtm2Yba/J 016198 129S6.Cg-Tg(Camk2a-tTA)1Mmay/JlwsJ 011008 B6.129P2(Cg)-Gt(ROSA)26Sortm1(tTA)Roos/J 009602 B6.129S4(Cg)-Kcnn2tm2Jpad/J 009603 B6.129S4-Kcnn3tm1Jpad/J 008227 B6.129S4-Ppargtm3Yba/J 016868 B6.Cg-Ssttm1.2(tTA2)Hze/J 007004 B6.Cg-Tg(Camk2a-tTA)1Mmay/DboJ 003767 B6.Cg-Tg(Eno2tTA)5021Nes/J 003763 B6.Cg-Tg(Eno2tTA)5030Nes/J 018306 B6.Cg-Tg(Fos-tTA,Fos-EGFP*)1Mmay/J 005964 B6.Cg-Tg(GFAP-tTA)110Pop/J 002618 B6.Cg-Tg(MMTVtTA)1Mam/J 008284 B6.Cg-Tg(Scg2-tTA)1Jt/J 023970 B6.Cg-Tg(Sirpa-tTA)AUmri/J 023971 B6.Cg-Tg(Sirpa-tTA)SUmri/J 006361 B6.Cg-Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/J 017722 B6.Cg-Tg(Tal1-tTA)19Dgt/J 017754 B6;129-Omptm1(tTA)Gogo/J 007585 B6;129S4-Npytm2Rpa/J 002709 B6;C3-Tg(TettTALuc)1Dgs/J 003010 B6;CBA-Tg(Camk2a-tTA)1Mmay/J 008344 B6;DBA-Tg(Fos-tTA,Fos-EGFP*)1Mmay Tg(tetO-lacZ,tTA*)1Mmay/J 010573 B6;SJL-Tg(Prl-tTA)6-5Jek/J 008082 B6;SJL-Tg(Tagln-tTA)1Mrab Tg(tetO-Mcpt1)1Mrab/J 008603 C.129P2(B6)-Gt(ROSA)26Sortm1(tTA)Roos/J 010712 C57BL/6-Tg(Camk2a-tTA)1Stl/J 013585 FVB-Tg(Cdh5-tTA)D5Lbjn/J 005625 FVB-Tg(Pcp2-tTA)3Horr/J 025105 FVB.Cg-Tg(Camk2a-tTA)1Mmay/DboJ 003170 FVB.Cg-Tg(Myh6-tTA)6Smbf/J 006209 FVB.Cg-Tg(Tal1-tTA)19Dgt/J 005942 FVB/N-Tg(Pf4-tTA/VP16)42Kra/J 004937 NOD.Cg-Tg(Ins2-tTA)1Doi/DoiJ 006999 STOCK Dbttm1Geh Tg(Cebpb-tTA)5Bjd Tg(tetO-DBT)A1Geh/J 008335 STOCK Foxa2tm1.1(rtTa)Moon/J 008600 STOCK Gt(ROSA)26Sortm1(tTA)Roos/J 024108 STOCK Igs7tm93.1(tetO-GCaMP6f)Hze Tg(Camk2a-tTA)1Mmay/J 005701 STOCK Pdx1tm1Macd/J 014092 STOCK Tg(ACTB-tTA2,-MAPT/lacZ)1Luo/J 003271 STOCK Tg(CMV-tTA)3Bjd/J 024854 STOCK Tg(Camk2a-tTA)1Mmay Tg(tetO-MAPT*P301L)#Kha/J 018124 STOCK Tg(Prnp-tTA)F959Sbp/J 009606 STOCK Tg(Six2-EGFP/cre)1Amc/J 003275 STOCK Tg(tetL)1Bjd/J 003274 STOCK Tg(tetNZL)2Bjd/JView Strains carrying other alleles of tTA (46 strains)
View Research Applications
|Allele Name||transgene insertion 5, Hermann Bujard|
|Allele Type||Transgenic (Transactivator)|
|Common Name(s)||LAP-tTA; Tg(tTALap)5Uh; g(tTALap)5Bjd;|
|Mutation Made By||Dr. Hermann Bujard, Universit┐t Heidelberg|
|Strain of Origin||NMRI|
|Site of Expression||Expresses tTA at high levels in the liver; see Stock No. 003563|
|Expressed Gene||tTA, tetracycline-controlled transactivator, E. coli|
|The tetracycline-resistance gene (TetR), arose from chemically mutated Escherichia coli genome which was screened for tetracycline dependence (Gossen and Bujard, 1992). TetR was fused at the C-terminus with the viral co-activator, virion protein 16 of the herpes simplex virus (VP-16). The tetracycline-inhibitable transcription factor is a component of a bigenic system that allows doxycycline (a tetracycline analog) regulatable expression of genes that are under the direction of the tetracycline responsive promoter (TetOp)promoter.|
|Promoter||Cebpb, CCAAT/enhancer binding protein (C/EBP), beta, rat|
|General Note||Transgenic mice on a C57BL/6J background are viable and fertile, and express tTA in the liver.|
|Molecular Note||This transgene contains the gene encoding the tetracycline regulated transactivator protein (tTA) driven by the rat Cebpb promoter (previously called liver-enriched activator protein). [MGI Ref ID J:93000]|
Kistner A; Gossen M; Zimmermann F; Jerecic J; Ullmer C; Lubbert H; Bujard H. 1996. Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice. Proc Natl Acad Sci U S A 93(20):10933-8. [PubMed: 8855286] [MGI Ref ID J:93000]
Beer S; Komatsubara K; Bellovin DI; Kurobe M; Sylvester K; Felsher DW. 2008. Hepatotoxin-induced changes in the adult murine liver promote MYC-induced tumorigenesis. PLoS ONE 3(6):e2493. [PubMed: 18560566] [MGI Ref ID J:139884]
Beer S; Zetterberg A; Ihrie RA; McTaggart RA; Yang Q; Bradon N; Arvanitis C; Attardi LD; Feng S; Ruebner B; Cardiff RD; Felsher DW. 2004. Developmental Context Determines Latency of MYC-Induced Tumorigenesis. PLoS Biol 2(11):E332. [PubMed: 15455033] [MGI Ref ID J:93372]
Cairo S; Armengol C; De Reynies A; Wei Y; Thomas E; Renard CA; Goga A; Balakrishnan A; Semeraro M; Gresh L; Pontoglio M; Strick-Marchand H; Levillayer F; Nouet Y; Rickman D; Gauthier F; Branchereau S; Brugieres L; Laithier V; Bouvier R; Boman F; Basso G;Michiels JF; Hofman P; Arbez-Gindre F; Jouan H; Rousselet-Chapeau MC; Berrebi D; Marcellin L; Plenat F; Zachar D; Joubert M; Selves J; Pasquier D; Bioulac-Sage P; Grotzer M; Childs M; Fabre M; Buendia MA. 2008. Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in aggressive childhood liver cancer. Cancer Cell 14(6):471-84. [PubMed: 19061838] [MGI Ref ID J:142029]
Cao Z; Fan-Minogue H; Bellovin DI; Yevtodiyenko A; Arzeno J; Yang Q; Gambhir SS; Felsher DW. 2011. MYC Phosphorylation, Activation, and Tumorigenic Potential in Hepatocellular Carcinoma Are Regulated by HMG-CoA Reductase. Cancer Res 71(6):2286-97. [PubMed: 21262914] [MGI Ref ID J:170758]
Carpenter B; Lin Y; Stoll S; Raffai RL; McCuskey R; Wang R. 2005. VEGF is crucial for the hepatic vascular development required for lipoprotein uptake. Development 132(14):3293-303. [PubMed: 15944181] [MGI Ref ID J:100427]
Chow EK; Zhang XQ; Chen M; Lam R; Robinson E; Huang H; Schaffer D; Osawa E; Goga A; Ho D. 2011. Nanodiamond therapeutic delivery agents mediate enhanced chemoresistant tumor treatment. Sci Transl Med 3(73):73ra21. [PubMed: 21389265] [MGI Ref ID J:170992]
Dickins RA; McJunkin K; Hernando E; Premsrirut PK; Krizhanovsky V; Burgess DJ; Kim SY; Cordon-Cardo C; Zender L; Hannon GJ; Lowe SW. 2007. Tissue-specific and reversible RNA interference in transgenic mice. Nat Genet 39(7):914-21. [PubMed: 17572676] [MGI Ref ID J:123006]
Hasenfuss SC; Bakiri L; Thomsen MK; Hamacher R; Wagner EF. 2014. Activator Protein 1 transcription factor Fos-related antigen 1 (Fra-1) is dispensable for murine liver fibrosis, but modulates xenobiotic metabolism. Hepatology 59(1):261-73. [PubMed: 23703832] [MGI Ref ID J:213764]
Hasenfuss SC; Bakiri L; Thomsen MK; Williams EG; Auwerx J; Wagner EF. 2014. Regulation of steatohepatitis and PPARgamma signaling by distinct AP-1 dimers. Cell Metab 19(1):84-95. [PubMed: 24411941] [MGI Ref ID J:210545]
Homanics GE; Skvorak K; Ferguson C; Watkins S; Paul HS. 2006. Production and characterization of murine models of classic and intermediate maple syrup urine disease. BMC Med Genet 7:33. [PubMed: 16579849] [MGI Ref ID J:119973]
Hsu SH; Wang B; Kota J; Yu J; Costinean S; Kutay H; Yu L; Bai S; La Perle K; Chivukula RR; Mao H; Wei M; Clark KR; Mendell JR; Caligiuri MA; Jacob ST; Mendell JT; Ghoshal K. 2012. Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J Clin Invest 122(8):2871-83. [PubMed: 22820288] [MGI Ref ID J:190067]
Hu S; Balakrishnan A; Bok RA; Anderton B; Larson PE; Nelson SJ; Kurhanewicz J; Vigneron DB; Goga A. 2011. 13C-pyruvate imaging reveals alterations in glycolysis that precede c-Myc-induced tumor formation and regression. Cell Metab 14(1):131-42. [PubMed: 21723511] [MGI Ref ID J:176076]
Ivanovska I; Zhang C; Liu AM; Wong KF; Lee NP; Lewis P; Philippar U; Bansal D; Buser C; Scott M; Mao M; Poon RT; Fan ST; Cleary MA; Luk JM; Dai H. 2011. Gene signatures derived from a c-MET-driven liver cancer mouse model predict survival of patients with hepatocellular carcinoma. PLoS One 6(9):e24582. [PubMed: 21949730] [MGI Ref ID J:177679]
Kim A; Joseph S; Khan A; Epstein CJ; Sobel R; Huang TT. 2010. Enhanced expression of mitochondrial superoxide dismutase leads to prolonged in vivo cell cycle progression and up-regulation of mitochondrial thioredoxin. Free Radic Biol Med 48(11):1501-12. [PubMed: 20188820] [MGI Ref ID J:160351]
Kornmann B; Schaad O; Bujard H; Takahashi JS; Schibler U. 2007. System-driven and oscillator-dependent circadian transcription in mice with a conditionally active liver clock. PLoS Biol 5(2):e34. [PubMed: 17298173] [MGI Ref ID J:141590]
Kota J; Chivukula RR; O'Donnell KA; Wentzel EA; Montgomery CL; Hwang HW; Chang TC; Vivekanandan P; Torbenson M; Clark KR; Mendell JR; Mendell JT. 2009. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137(6):1005-17. [PubMed: 19524505] [MGI Ref ID J:151413]
May D; Djonov V; Zamir G; Bala M; Safadi R; Sklair-Levy M; Keshet E. 2011. A transgenic model for conditional induction and rescue of portal hypertension reveals a role of VEGF-mediated regulation of sinusoidal fenestrations. PLoS One 6(7):e21478. [PubMed: 21779329] [MGI Ref ID J:176264]
Ney JT; Schmidt T; Kurts C; Zhou Q; Eckert D; Felsher DW; Schorle H; Knolle P; Tuting T; Barchet W; Buttner R; Limmer A; Gutgemann I. 2009. Autochthonous liver tumors induce systemic T cell tolerance associated with T cell receptor down-modulation. Hepatology 49(2):471-81. [PubMed: 19105207] [MGI Ref ID J:186226]
Nguyen LH; Robinton DA; Seligson MT; Wu L; Li L; Rakheja D; Comerford SA; Ramezani S; Sun X; Parikh MS; Yang EH; Powers JT; Shinoda G; Shah SP; Hammer RE; Daley GQ; Zhu H. 2014. Lin28b is sufficient to drive liver cancer and necessary for its maintenance in murine models. Cancer Cell 26(2):248-61. [PubMed: 25117712] [MGI Ref ID J:214596]
O'Donnell KA; Keng VW; York B; Reineke EL; Seo D; Fan D; Silverstein KA; Schrum CT; Xie WR; Mularoni L; Wheelan SJ; Torbenson MS; O'Malley BW; Largaespada DA; Boeke JD. 2012. A Sleeping Beauty mutagenesis screen reveals a tumor suppressor role for Ncoa2/Src-2 in liver cancer. Proc Natl Acad Sci U S A 109(21):E1377-86. [PubMed: 22556267] [MGI Ref ID J:184782]
Ribeiro AC; Ceccarini G; Dupre C; Friedman JM; Pfaff DW; Mark AL. 2011. Contrasting effects of leptin on food anticipatory and total locomotor activity. PLoS One 6(8):e23364. [PubMed: 21853117] [MGI Ref ID J:176508]
Roy CN; Mak HH; Akpan I; Losyev G; Zurakowski D; Andrews NC. 2007. Hepcidin antimicrobial peptide transgenic mice exhibit features of the anemia of inflammation. Blood 109(9):4038-44. [PubMed: 17218383] [MGI Ref ID J:145326]
Saddic LA; Wirt S; Vogel H; Felsher DW; Sage J. 2011. Functional Interactions between Retinoblastoma and c-MYC in a Mouse Model of Hepatocellular Carcinoma. PLoS One 6(5):e19758. [PubMed: 21573126] [MGI Ref ID J:172430]
Schonig K; Kentner D; Gossen M; Baldinger T; Miao J; Welzel K; Vente A; Bartsch D; Bujard H. 2011. Development of a BAC vector for integration-independent and tight regulation of transgenes in rodents via the Tet system. Transgenic Res 20(3):709-20. [PubMed: 20640885] [MGI Ref ID J:172622]
Shachaf CM; Kopelman AM; Arvanitis C; Karlsson A; Beer S; Mandl S; Bachmann MH; Borowsky AD; Ruebner B; Cardiff RD; Yang Q; Bishop JM; Contag CH; Felsher DW. 2004. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 431(7012):1112-7. [PubMed: 15475948] [MGI Ref ID J:93899]
Skvorak KJ; Hager EJ; Arning E; Bottiglieri T; Paul HS; Strom SC; Homanics GE; Sun Q; Jansen EE; Jakobs C; Zinnanti WJ; Gibson KM. 2009. Hepatocyte transplantation (HTx) corrects selected neurometabolic abnormalities in murine intermediate maple syrup urine disease (iMSUD). Biochim Biophys Acta 1792(10):1004-10. [PubMed: 19699299] [MGI Ref ID J:164850]
Sun Y; Quinn B; Xu YH; Leonova T; Witte DP; Grabowski GA. 2006. Conditional expression of human acid beta-glucosidase improves the visceral phenotype in a Gaucher disease mouse model. J Lipid Res 47(10):2161-70. [PubMed: 16861620] [MGI Ref ID J:116525]
Tao GZ; Lehwald N; Jang KY; Baek J; Xu B; Omary MB; Sylvester KG. 2013. Wnt/beta-catenin signaling protects mouse liver against oxidative stress-induced apoptosis through the inhibition of forkhead transcription factor FoxO3. J Biol Chem 288(24):17214-24. [PubMed: 23620592] [MGI Ref ID J:199603]
Tilli MT; Furth PA. 2003. Conditional mouse models demonstrate oncogene-dependent differences in tumor maintenance and recurrence. Breast Cancer Res 5(4):202-5. [PubMed: 12817992] [MGI Ref ID J:84503]
Tward AD; Jones KD; Yant S; Cheung ST; Fan ST; Chen X; Kay MA; Wang R; Bishop JM. 2007. Distinct pathways of genomic progression to benign and malignant tumors of the liver. Proc Natl Acad Sci U S A 104(37):14771-14776. [PubMed: 17785413] [MGI Ref ID J:124960]
Wang R; Ferrell LD; Faouzi S; Maher JJ; Bishop JM. 2001. Activation of the met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice. J Cell Biol 153(5):1023-34. [PubMed: 11381087] [MGI Ref ID J:69731]
Woodard LE; Keravala A; Jung WE; Wapinski OL; Yang Q; Felsher DW; Calos MP. 2010. Impact of hydrodynamic injection and phiC31 integrase on tumor latency in a mouse model of MYC-induced hepatocellular carcinoma. PLoS One 5(6):e11367. [PubMed: 20614008] [MGI Ref ID J:161998]
Yang YA; Zhang GM; Feigenbaum L; Zhang YE. 2006. Smad3 reduces susceptibility to hepatocarcinoma by sensitizing hepatocytes to apoptosis through downregulation of Bcl-2. Cancer Cell 9(6):445-57. [PubMed: 16766264] [MGI Ref ID J:110133]
Animal Health ReportsProduction of mice from cryopreserved embryos or sperm occurs in a maximum barrier room, G200.
|Pricing for USA, Canada and Mexico shipping destinations|
Cryopreserved Mice - Ready for Recovery
Price (US dollars $) Cryorecovery* $2525.00
At least two mice that carry the mutation (if it is a mutant strain) will be provided. Their genotypes may not reflect those discussed in the strain description. Please inquire for possible genotypes and see additional details below.
Cryorecovery - Standard.
Progeny testing is not required.
The average number of mice provided from recovery of our cryopreserved strains is 10. The total number of animals provided, their gender and genotype will vary. We will fulfill your order by providing at least two pair of mice, at least one animal of each pair carrying the mutation of interest. Please inquire if larger numbers of animals with specific genotype and genders are needed. Animals typically ship between 10 and 14 weeks from the date of your order. If a second cryorecovery is needed in order to provide the minimum number of animals, animals will ship within 25 weeks. IMPORTANT NOTE: The genotypes of animals provided may not reflect the mating scheme utilized by The Jackson Laboratory prior to cryopreservation, or that discussed in the strain description. Please inquire about possible genotypes which will be recovered for this specific strain. The Jackson Laboratory cannot guarantee the reproductive success of mice shipped to your facility. If the mice are lost after the first three days (post-arrival) or do not produce progeny at your facility, a new order and fee will be necessary.
Cryorecovery to establish a Dedicated Supply for greater quantities of mice. Mice recovered can be used to establish a dedicated colony to contractually supply you mice according to your requirements. Price by quotation. For more information on Dedicated Supply, please contact JAX® Services, Tel: 1-800-422-6423 (from U.S.A., Canada or Puerto Rico only) or 1-207-288-5845 (from any location).
|Pricing for International shipping destinations|
Cryopreserved Mice - Ready for Recovery
Price (US dollars $) Cryorecovery* $3283.00
Cryorecovery - Standard.
Progeny testing is not required.
For Licensing and Use Restrictions view the link(s) below:
- Use of MICE by companies or for-profit entities requires a license prior to shipping.
MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.
In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of mice, products or services, JACKSON will, at its option, provide credit or replacement for the mice or product received or the services provided.
In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS or services from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.
MICE and PRODUCTS are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.
The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or services. In addition, special terms and conditions of sale of certain MICE, PRODUCTS or services may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and services by JACKSON, and by its licensees and distributors.
Acceptance of delivery of MICE, PRODUCTS or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or services by JACKSON.